Clinical trials
Metastatic Prostate Cancer clinical trials
Below are recruiting metastatic prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 717 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06346197RecruitingPhase 3
Immunotherapy combo for advanced MSI-H stomach/esophageal cancer
This trial tests a combination of immune checkpoint inhibitors (nivolumab, botensilimab, and balstilimab) plus chemotherapy for people with advanced stomach or esophageal cancer that has a specific genetic instability (MSI-H/dMMR) and expresses PD-L1. It may be an option for those who haven't had prior immunotherapy or chemotherapy for advanced disease.
BrestAges 18 years+ - NCT06585007RecruitingPhase 3
Radiation for limited cancer growth in castration-resistant prostate cancer
This trial tests whether giving focused radiation to limited areas of cancer growth (up to 3 spots) can help control the disease in men with castration-resistant prostate cancer. You may be eligible if your cancer is growing slowly and you are already on hormone therapy.
LeuvenAges 18 years+ - NCT06259279Recruiting
High impact training for prostate cancer with bone spread
This trial tests whether high impact exercise can help men with prostate cancer that has spread to their bones. You may qualify if you have bone metastases and are on hormone therapy.
Herlev, HerlevAges 18 years+ - NCT07240857Enrolling by invitationEarly Phase 1
CAR-T cell injection for advanced prostate cancer
This trial tests a new treatment called ACT#001 CAR-T cells, given as a local injection, for prostate cancer that has stopped responding to hormone therapy. It aims to see if this therapy is safe and can help shrink tumors.
Hangzhou, ZhejiangAges 18 years+ - NCT07205783Enrolling by invitation
Comparing surgery and radiation for early prostate cancer
This trial compares two standard treatments for prostate cancer that hasn't spread: surgery to remove the prostate (radical prostatectomy) and radiation therapy (curative radiotherapy). It looks back at past patients to see which treatment worked better.
SohagAges 40 years+ - NCT05997615RecruitingPhase 1
Study of VIR-5500 for advanced prostate cancer
This trial tests VIR-5500 (AMX-500), a new targeted treatment, in men with prostate cancer that has spread and stopped responding to standard therapies. The goal is to see if it is safe and if it may help shrink or slow the cancer.
Duarte, CaliforniaAges 18 years+ - NCT04861194Recruiting
Test treatment plans to preserve erections during prostate radiation
This trial studies ways to help preserve erectile function while you receive radiation treatment for prostate cancer. It may help by aiming to protect erections, especially for people at low to intermediate risk.
Utrecht, UtrechtAges 18 years+ - NCT04610372Recruiting
Targeted radiation plus hormone therapy for prostate cancer spread
This study compares different ways of giving radiation (SABR or brachytherapy) along with long-term hormone therapy for men whose prostate cancer has spread to a limited number of spots in the body. It aims to see which radiation approach controls the cancer as well as possible while keeping quality of life in mind.
Kelowna, British ColumbiaAges 18 years+ - NCT04363164RecruitingPhase 2
Testosterone then enzalutamide to stop prostate cancer spread
This Phase 2 trial tests whether giving testosterone first, then enzalutamide (a prostate cancer hormone-blocking pill), can slow or prevent worsening metastatic prostate cancer. It is designed for men whose cancer progressed despite ongoing hormone-suppression treatment.
San Diego, CaliforniaAges 18–90 - NCT00588185Recruiting
Pet scans for advanced prostate or salivary gland cancer
This study uses special PET scans to get a detailed picture of prostate or salivary gland cancer that is getting worse. The scans may help doctors see the cancer more clearly and plan better treatment.
Basking Ridge, New JerseyAges Any age - NCT07860528Recruiting
High-dose brachytherapy for prostate cancer that has returned
This trial tests a type of radiation therapy called high-dose-rate brachytherapy, which is given to men whose prostate cancer has come back after their first treatment. It aims to control the cancer while keeping side effects low.
Benidorm, AlicanteAges 18 years+ - NCT06085664RecruitingPhase 1/Phase 2
Immunotherapy before prostate cancer surgery
This trial tests a new immunotherapy drug (REGN5678) given before surgery to men with high-risk prostate cancer that hasn't spread. The goal is to see if the drug can shrink or control the cancer before the prostate is removed.
Houston, TexasAges 18 years+ - NCT06422455Recruiting
Genetic testing for underserved cancer patients
This study offers free genetic testing to cancer patients and their healthcare providers. It aims to help people who may not have easy access to genetic testing understand their cancer risk.
Los Angeles, CaliforniaAges 18 years+ - NCT06470243RecruitingPhase 3
Adding carboplatin to cabazitaxel for advanced prostate cancer
This study tests whether adding a chemotherapy drug called carboplatin to another chemotherapy called cabazitaxel works better than cabazitaxel alone for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. All participants must have already had docetaxel chemotherapy.
Fayetteville, ArkansasAges 18 years+ - NCT06177015RecruitingPhase 3
Darolutamide with chemo for metastatic prostate cancer
This trial tests a new way of using darolutamide (a hormone therapy) together with standard chemotherapy (docetaxel) and hormone therapy (ADT) for men with prostate cancer that has spread. The goal is to see if taking darolutamide on an intermittent schedule works as well as continuous treatment.
Nanjing, JiangsuAges 40–80 - NCT06350825RecruitingPhase 3
Surgery plus hormone therapy for advanced prostate cancer
This study tests if removing the prostate and giving strong hormone therapy works better than hormone therapy alone for men whose prostate cancer has spread. It aims to improve how long patients live without the cancer worsening.
Nanjing, JiangsuAges 18–75 - NCT06655259RecruitingPhase 2
TURP with standard therapy for metastatic prostate cancer
This trial tests whether adding a surgery called TURP (transurethral resection of the prostate) to the usual hormone therapy and chemotherapy can help men with metastatic prostate cancer that has spread to lymph nodes, bone, or other organs. The surgery helps relieve urinary symptoms and may improve how well the cancer responds to treatment.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06496581RecruitingPhase 3
Adding a targeted radiation drug for prostate cancer that hasn't responded well to initial treatment
This trial tests if adding a radioactive drug called 177Lu-PSMA-617 to standard therapy helps men whose prostate cancer has spread and hasn't responded well to initial hormone therapy. It's for men whose PSA level is still detectable after 6-8 months of treatment.
AngersAges 18–80 - NCT07354594RecruitingPhase 2
Combining radiation therapies for advanced prostate cancer
This trial tests the combination of two radiation treatments for prostate cancer that has spread. The goal is to see if adding a targeted external beam can improve outcomes for patients who are already receiving a specific radioactive drug therapy (177Lu-PSMA).
Montreal, QuebecAges Any age - NCT07290270Recruiting
Real-world use of lutetium therapy for advanced prostate cancer
This study follows men with advanced prostate cancer who are receiving a new radioactive treatment called lutetium (177Lu) vipivotide tetraxetan. The goal is to see how well the treatment works in everyday practice, and to gather information on safety and effectiveness.
Shanghai, Shanghai MunicipalityAges 18–99 - NCT07209176Recruiting
Why men may not get genetic testing for prostate cancer
This study looks at why some men with metastatic prostate cancer do or don't get a genetic test called NGS. It aims to find barriers to testing, so doctors can better help patients in the future.
Baltimore, MarylandAges 18 years+ - NCT07096128RecruitingPhase 1
PSMA-targeted radioactive injection for advanced prostate cancer
This early-phase study tests a new radioactive drug that targets PSMA, a protein on prostate cancer cells, to see if it can shrink tumors and slow the disease. It may be an option for men with advanced prostate cancer that has not responded to hormone therapy and possibly chemotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06992232RecruitingPhase 2
Radiation or surgery plus hormone therapy for prostate cancer that has spread
This trial tests whether giving intense hormone therapy along with either radiation or surgery can help men with prostate cancer that has spread to a limited number of spots (10 or fewer) but not to organs like the liver or lungs. The goal is to treat both the main tumor and the visible metastatic spots more aggressively.
Nanjing, JiangsuAges 18–80 - NCT06832774RecruitingPhase 2
Hormone therapy plus local treatment for advanced prostate cancer
This study tests adding a targeted local treatment (like radiation or surgery) to standard hormone therapy for men with advanced prostate cancer that still shows up on a special scan. The goal is to see if this combination helps control the cancer better.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic prostate cancer?
- Yes. Clin2 currently lists 717 recruiting metastatic prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Castration-resistant Prostate Cancer
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Prostate Cancer Metastatic Disease
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Metastatic Castration-Resistant Prostate Cancer Patients
- Non-metastatic Castration-resistant Prostate Cancer
- Metastatic Breast Cancer
- Metastatic Colorectal Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.